in the clinic. However, the emergence of multidrug-resistant strains of Gram-positive bacteria caused the nosocomial infection has become a major concern.1,2) Antimicrobial agents like vancomycin, quinupristin/dalfopristin (Synercid)3) and linezolid (Zyvox)4) were developed to manage infections such as complicated skin and skin structure infection and life-threatening bacteremia. The recently isolated pathogens from hospitals are likely to reduce susceptibility to those drugs.5) Therefore, urgent need of a new agent with good safety and potent efficacy against MRSA and VRE has led us to search for a new cephalosporin. Herein, we described the synthesis of cephalosporins having the (E)-thiovinyl linker with pyrimidines ring at C-3 position and aminothiazole rings at C-7 position and their antibacterial activities as well.
Chemistry
Cephalosporin with the (E)-thiovinyl linker at C-3 position were known to possess good in vitro antibacterial activities against MRSA and vancomycin-resistant Enterococcus faecalis.6) Therefore we applied the (E)-thiovinyl linker with pyrimidines at C-3 position to develop a new and effective cephalosporin with excellent activities against MRSA and VRE in our communication. This approach would show the scope of activities of cephalosporins with the (E)-thiovinyl linker having pyrimidines at C-3 position. All the cephalosporins and pyrimidinethiols7) we prepared were described in Fig. 1 Fig. 1 was too sluggish or turned out to
give low chemical yield (5-10%), transformation of vinyl triflate to vinyl sulfide was proven to be successful. It was worthwhile to note that vinyl triflate was an appropriate leaving group to handle with good stability. The generated vinyl triflate 7 was reacted with pyrimidinethiol 2a to afford pyrimidinethiol 9 was subjected to bromide 10, followed by protection with Boc2O and selective hydrolysis with sodium Table 1. A. CHO et al. reported that the incorporation of a basic aminopyridine at C-7 position afforded good potency against MRSA and acceptable solubility for intravenous administration.9) When 1h, 1i and 1j attached with a basic chain in pyrimidines were tested, they showed excellent antibacterial activities against all the Gram-positive strains in Table 1 Table 2 . Among them, 1e and 1i displayed disappointing in vivo activities due to low pharmacokinetic profile in mice. 1c, 1d and 1f showed moderate in vivo activity but inferior in vivo activity to vancomycin although they have good in vitro activity against MRSA K283. Cephalosporin 1j having a basic chain in pyrimidine was proven to exhibit almost the same in vivo activity (PD50: 2.5mg/kg) with vancomycin in this model. Among them, intravenous administration of 1c, 1f and 1j in rats with 20mg/kg resulted in AUC (mg min/ml) of 4972, 5573 and 924, and half time (minute) of 47, 55 and 16, respectively. 1 c, 1f and 1j were selected for the further investigation as our new candidates against nosocomial infection based on in vivo experiment and pharmacokinetic data.
In conclusion, cephalosporin having the (E)-2-thiovinyl linker attached with pyrimidines at C-3 position was found to possess excellent in vitro activities and good in vivo activity against MRSA, MRSE and VREF.
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